All In Biotech

Drug Trial Radar · NCT00158730

Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment

Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients

Last checked: Nov 20, 2026Latest source record: Nov 18, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

800

Actual

Start

Apr 2003

Primary completion

Not stated

Study completion Jan 2005

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 1 month
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate and compare two AmBisome dosing regimens for the initial treatment of invasive aspergillosis and other filamentous fungal infections diagnosed by modified EORTC criteria in immunocompromised patients, as determined by overall response rates at end of course of treatment.

Conditions

  • Invasive Aspergillosis
  • Other Fungal Infections

Interventions

  • AmBisomeDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate two regimens determined by overall response rates at end of tx.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.